Cognition Therapeutics 주식 (NASDAQ: CGTX)

에 대한 최신 뉴스 Cognition Therapeutics (NASDAQ:CGTX) 주식

Cognition Therapeutics

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics Inc

In the last three months, 43 analysts have published ratings on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">18</td>
<td align="right">15</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $988.72, a high estimate of $1175.00, and a low estimate of $755.00. This current average reflects an increase of 6.51% from the previous average price target of $928.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1734559221_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Costco Wholesale is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1060.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$1000.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$900.00</td>
<td>$880.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$1090.00</td>
<td>$975.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$935.00</td>
<td>$909.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$940.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$1095.00</td>
<td>$1005.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1175.00</td>
<td>$1075.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$907.00</td>
<td>$755.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1030.00</td>
<td>$1020.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1050.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1075.00</td>
<td>$980.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$1145.00</td>
<td>$1050.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$935.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$950.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1075.00</td>
<td>$975.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1050.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1075.00</td>
<td>$980.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Dean Rosenblum</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1016.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Announces</td>
<td>Buy</td>
<td>$1065.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$880.00</td>
<td>$880.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$935.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$980.00</td>
<td>$955.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$990.00</td>
<td>$985.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$975.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$755.00</td>
<td>$676.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$880.00</td>
<td>$780.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$995.00</td>
<td>$876.00</td>
</tr>
<tr>
<td>George Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$850.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$850.00</td>
<td>$830.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$909.00</td>
<td>$873.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$980.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$925.00</td>
<td>$915.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$1005.00</td>
<td>$975.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$873.00</td>
<td>$873.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$950.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Costco Wholesale. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Costco Wholesale compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Costco Wholesale's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Costco Wholesale's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Costco Wholesale analyst ratings.</a>
<h2>Get to Know Costco Wholesale Better</h2>
Costco operates a membership-based, no-frills retail model, predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given Costco's frugal cost structure, the firm is able to price its merchandise below competing retailers, driving high sales volume per warehouse and allowing the retailer to generate strong profits on thin margins. Costco operates over 600 warehouses in the United States and boasts over 60% market share in the domestic warehouse club industry. Internationally, Costco operates another 270 warehouses, primarily in markets such as Canada, Mexico, Japan, and the UK.
<h3>Financial Insights: Costco Wholesale</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Costco Wholesale's remarkable performance in 3 months is evident. As of 31 August, 2024, the company achieved an impressive revenue growth rate of 0.96%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Costco Wholesale's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.95% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 10.37%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Costco Wholesale's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.42% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Costco Wholesale's debt-to-equity ratio is below the industry average at 0.35, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

COST

Forecasting The Future: 43 Analyst Projections For Costco Wholesale

In the preceding three months, 14 analysts have released ratings for Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Fidelity National Info and provided 12-month price targets. The average target is $98.36, accompanied by a high estimate of $126.00 and a low estimate of $86.00. Marking an increase of 12.46%, the current average surpasses the previous average price target of $87.46. 
<img src="https://www.benzinga.com/files/images/story/2024/1734559212_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Fidelity National Info. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$92.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Dominick Gabriele</td>
<td>Compass Point</td>
<td>Announces</td>
<td>Buy</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$86.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Vasundhara Govil</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$87.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$103.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>David Koning</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Trevor Williams</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Fidelity National Info. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Fidelity National Info compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Fidelity National Info's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Fidelity National Info's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FIS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fidelity National Info analyst ratings.</a>
<h2>Get to Know Fidelity National Info Better</h2>
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.
<h3>A Deep Dive into Fidelity National Info's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Fidelity National Info displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 3.13%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.72%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Fidelity National Info's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.33%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Fidelity National Info's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.65%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.66, Fidelity National Info adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Fidelity National Info: Insights From 14 Analyst Reviews

Alamos Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) has outperformed the market over the past 5 years by 12.33% on an annualized basis producing an average annual return of 25.12%. Currently, Alamos Gold has a market capitalization of $7.57 billion. 
Buying $1000 In AGI: If an investor had bought $1000 of AGI stock 5 years ago, it would be worth $3,196.46 today based on a price of $18.02 for AGI at the time of writing.
<h3>Alamos Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734559208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

As part of the previously announced Board refreshment plan, Lydia Thomas and Shirley Franklin will retire from the Board at the Annual Meeting.
Following the Annual Meeting, the Board will comprise nine directors, eight of whom are independent and eight of whom will have been elected in the last six years.

Management

Mueller Water Products Nominates Bentina Chisolm Terry And Leland Weaver To Join Board

Following the merger of CenterGroup with and into First Commonwealth, CenterBank will merge with and into First Commonwealth Bank.
The business combination will increase First Commonwealth's presence in the Cincinnati market, adding approximately $348.4 million of total assets, 3 branch locations, a loan production office and a mortgage office to First Commonwealth's Cincinnati franchise.&nbsp;

CenterGroup To Merge With And Into First Commonwealth In An All-stock Transaction Valued At $54.6M In Aggregate

"With the first quarter results roughly as anticipated, we are maintaining our full-year fiscal 2025 guidance, including total revenue and adjusted EBITDA growth of 5% at the midpoint of our guidance," the company said.
The company expects adjusted EBITDA in the range of $150 million to $160 million, and free cash flow between $85 million to $95 million.&nbsp; &nbsp;

Guidance

EPAC

Enerpac Tool Maintains FY25 Net Sales Outlook Of $610M - $625M (Est $622M), Organic Sales Growth Of Approximately 0% - 2%

Air Products Files Investor Presentation Highlighting Two-Pillar Strategy; Says Mantle Ridge's Proposed Nominees Would Remove Significant And Relevant Experience

Leading technology company NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is one of many companies that could be impacted by the future White House administration <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">under President-elect</a> Donald Trump.
Here's a look back at Nvidia's performance during Trump's last term and the potential gains investors could have realized.
What Happened: Nvidia was<a href="https://www.benzinga.com/markets/24/10/41595302/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-repea"> one of the best performing </a>S&amp;P 500 stocks in 2017, the first year Trump served as president of the United States.
The stock ranked ninth for the year with a +81% return in 2017. From the date of Trump's inauguration on Jan. 20, 2017 to President Joe Biden's inauguration on Jan. 20, 2021, Nvidia shares gained more than 400%.
Nvidia was<a href="https://www.benzinga.com/general/education/24/10/41665149/these-10-stocks-were-s-p-500s-top-performers-in-bidens-first-year-could-the-trend-continue-if-h"> also a top performing </a>S&amp;P 500 sock in 2021, the first year of Biden&#8217;s term in office. The stock ranked ninth once again, gaining 125.5% in 2021.
The semiconductor company has been one of the top performers in recent years, joining the $1 trillion market capitalization club <a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club">in May 2023 </a>and around a year later becoming the most valuable company in the world.
Nvidia <a href="https://www.benzinga.com/news/large-cap/24/11/41761849/nvidia-blows-past-apple-to-become-worlds-most-valuable-company">passed the milestone </a>of world's most valuable company several times in 2024 and is currently the third most valuable company in the world with a market capitalization of $3.16 trillion, trailing only Apple ($3.76 trillion) and Microsoft ($3.27 trillion).
While the impact of Trump on semiconductors, Taiwan, and the broader tech sector—and by extension, Nvidia&#8217;s share price—remains uncertain, history shows Nvidia tends to outperform in the first year of a new presidential term.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Investing $1,000 in NVDA: Investors who bought and held onto Nvidia shares when Trump was inaugurated as president of the United States would likely be happy with their return.
Nvidia stock traded at a split-adjusted high of $2.67 on Jan. 20, 2017. A $1,000 investment could have purchased 374.53 NVDA shares at the time.
Today, that investment would be worth $48,309.58 based on a $128.97 price for Nvidia at the time of writing. The investment would be up 4,731.0% over the last nearly eight years.
For comparison, the same $1,000 invested in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, would have delivered significantly lower returns.
The $1,000 investment could have bought 4.40 SPY shares, which would be worth $2,594.06 today based on a price of $589.56 for SPY at the time of writing. This investment would be up 159.4% over the same time period.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41190198/if-you-invested-1-000-in-nvidia-stock-when-jensen-huang-got-company-logo-tattoo-heres-how-much-">If You Invested $1,000 In Nvidia Stock When Jensen Huang Got Company Logo Tattoo, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Photo: Shutterstock

Education

Politics

NVDA

If You Invested $1,000 In NVIDIA Stock When Donald Trump Became President In 2017, Here's How Much You'd Have Now

Lennar Expects Q1 Gross Margin To Be 19.0% - 19.25%; Says Will Not Guide To Full Year Gross Margin At This Time Until Having Better Sense Of Market Conditions

Lennar Expects To Deliver 17,000 - 17,500 Homes For Q1 And 86,000 - 88,000 Homes For 2025, Including Impact Of Rausch Coleman Acquisition

Federal Reserve Chair Jerome Powell adopted a hawkish stance during his Wednesday press conference after the December Fed meeting, sparking a market bloodbath as the New York session <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">headed to the close.</a>
Although the Federal Reserve lowered interest rates by 0.25% to a range of 4.25%-4.5%, as widely anticipated, the updated economic projections suggest just two potential rate cuts in 2025 — down from four projected in September and fewer than the three anticipated by markets before the meeting.
Powell described the shift as &#8220;a new phase&#8221; for monetary policy, emphasizing that after 100 basis points of rate cuts in 2024, rates are now significantly closer to a neutral stance. 
Stocks tumbled across the board, the U.S. dollar soared to two-year highs and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) cratered over 5%, as investors digested the reality of a shift in the monetary policy stance by the Federal Reserve.
The CBOE Volatility Index, known as the VIX and Wall Street&#8217;s fear gauge, skyrocketed 58% to 25, reflecting a spike in investor uncertainty and heightened anxiety over the future of interest rates.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-1024x557.png" alt="" class="wp-image-698569" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-1536x836.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Wall Street Wipeout: Major Indices Slammed</h3>
The Dow Jones Industrial Average, as tracked by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), dropped 1,123 points, falling 2.6% to close at 42,326, marking its worst one-day drop since September 2022. Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) recorded the worst performance among blue-chip stocks, down 4.6%.
The S&amp;P 500 index — tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — fell 178 points, down 2.9% to 5,872, also marking its worst day since September 2022. Paycom Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) was the major laggard within the S&amp;P 500, down 10%.
The tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), experienced an even sharper drop of 3.6%, closing at 21,209 as interest rate-sensitive technology stocks took a beating. Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) tumbled 8.1%, marking the worst performance within the Nasdaq 100.
Every Magnificent Seven company ended the day in the red, collectively erasing more than $600 billion in market value on Wednesday.
Small caps in the Russell 2000 posted the steepest losses, plummeting 4.7% to 2,225. With Wednesday&#8217;s move, the iShares Russell 2000 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NASDAQ">IWM</a>) has fully erased the post-election rally.
All major U.S. equity sectors finished in the red. 
Consumer Discretionary stocks suffered the most, plunging 4.5%, followed by Real Estate, which dropped 4% as rising rates weigh heavily on growth-oriented and interest-rate-sensitive industries.
Technology, the largest sector by market capitalization, fell 3.2%, with chipmakers and software companies bearing the brunt of the selloff. 
Communications and Materials both declined 2.9%, while Financials dropped 3%, reflecting pressure across cyclical areas of the market.
Even traditionally defensive sectors failed to escape the selloff. Utilities and Consumer Staples fell 2.4% and 1.5%, respectively.
<h3 class="wp-block-heading">Dollar Surges To 2-Year Highs, Hammers Gold And Bitcoin</h3>
The U.S. dollar emerged as the day's clear winner, with the dollar index (DXY), followed by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), climbing 1.2% to reach its highest level since November 2022.
As the greenback rallied, gold failed to provide a safe haven, falling 2.1% to $2,580 per ounce, while silver dropped 3.5%.
Risk-off sentiment extended into alternative assets. Bitcoin plunged 5.5%, trading just above $101,500.
During the press conference, Powell was asked whether the U.S. government should consider building a strategic reserve of Bitcoin. Powell quickly dismissed the idea, making it clear that such a move is not on the Fed&#8217;s radar.
"We're not allowed to own Bitcoin," Powell said, emphasizing the legal and structural limitations of the Federal Reserve. "The Federal Reserve Act dictates what we can own, and we're not seeking any changes to that law."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">Fed Slashes Interest Rates By 0.25% As Predicted: December Dot Plot Flags Only 2 Potential Cuts In 2025</a></li>
</ul>
Illustration generated with AI via Dall-E.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Broad U.S. Equity ETFs

Commodities

Currency ETFs

Econ #s

Economics

Federal Reserve

Markets

Movers

ETFs

$BTC

AMZN

SPDR Dow Jones Industrial Average ETF Trust

PAYC

TSLA

PowerShares DB US Dollar Index Bullish Fund

Powell Triggers Market Carnage: VIX Spikes 58%, Stocks Plummet, Dollar Hits 2-Year Highs, Bitcoin Nosedives

TURN

180 Degree Capital Says Press Release Issued By Marlton Contains Number Of Inaccuracies And Distortions

The proposed decision is scheduled to be voted on by the CPUC on January 16, 2025. When a final decision is issued by the CPUC, the new rates will be effective and retroactive to January 1, 2023.&nbsp;
As a result, the impact from retroactive rates for the full year of 2023 and from the second-year rate increases through the nine months ended September 30, 2024 are expected at this time to be reflected in the 2024 fourth quarter results.

American States Water Reveals Proposed Decision Adopting Settlement Agreement In Its Electric Utility General Rate Case

The Q1 earnings report for Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) was released on Wednesday, December 18, 2024 at 04:30 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Enerpac Tool Group missed estimated earnings by -2.0%, reporting an EPS of $0.4 versus an estimate of $0.41.
Revenue was up $3.23 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
Last quarter the company missed on EPS by $0.03 which was followed by a 1.0% drop in the share price the next day.
Here's a look at Enerpac Tool Group's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.47</td>
<td>0.36</td>
<td>0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.50</td>
<td>0.47</td>
<td>0.36</td>
<td>0.39</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>156.70M</td>
<td>153.20M</td>
<td>141.10M</td>
<td>137.90M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>158.71M</td>
<td>150.39M</td>
<td>138.44M</td>
<td>141.97M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enerpac Tool Group <a href="https://www.benzinga.com/quote/EPAC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Enerpac Tool Group Q1 Earnings

Grocery Outlet Appoints Christopher Miller As Executive Vice President And CFO, Effective January 6, 2025

Buybacks

Tri Pointe Homes Board Approves New Stock Repurchase Program Of Up To $250M Of Common Stock Through December 31, 2025

Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.41 by 2.44 percent. This is a 2.56 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $145.20 million which beat the analyst consensus estimate of $144.40 million by 0.55 percent. This is a 2.27 percent increase over sales of $141.97 million the same period last year.

Earnings Beats

Earnings Misses

Enerpac Tool Group Q1 2025 Adj EPS $0.40 Misses $0.41 Estimate, Sales $145.20M Beat $144.40M Estimate

Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported quarterly earnings of $4.03 per share which missed the analyst consensus estimate of $4.16 by 3.12 percent. This is a 22.05 percent decrease over earnings of $5.17 per share from the same period last year. The company reported quarterly sales of $9.95 billion which missed the analyst consensus estimate of $10.08 billion by 1.35 percent. This is a 9.32 percent decrease over sales of $10.97 billion the same period last year.

Lennar Q4 2024 Adj EPS $4.03 Misses $4.16 Estimate, Sales $9.95B Miss $10.08B Estimate

Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) has outperformed the market over the past 15 years by 4.16% on an annualized basis producing an average annual return of 15.8%. Currently, Aon has a market capitalization of $76.25 billion. 
Buying $1000 In AON: If an investor had bought $1000 of AON stock 15 years ago, it would be worth $9,117.66 today based on a price of $352.58 for AON at the time of writing.
<h3>Aon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734557412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Aon Stock In The Last 15 Years

The Federal Reserve announced a widely anticipated 25-basis-point interest rate cut at its December meeting Wednesday, lowering the federal funds rate to a <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">range of 4.25% to 4.5%.</a>
The cut is the third consecutive reduction in borrowing costs following a 50-basis-point cut in September and a 25-basis-point move in November and brings rates to the lowest level since January 2023. 
Read Next: <a href="https://www.benzinga.com/general/market-summary/24/12/42535400/americans-bought-less-but-paid-more-says-peter-schiff-experts-digest-november-retail-sales-data">&#8216;Americans Bought Less But Paid More,&#8217; Says Peter Schiff: Experts Digest November Retail Sales Data</a>
Tthe Fed now projects two additional 0.25% rate cuts in 2025, a meaningful revision from the full percentage point of cuts expected in September. Markets reacted sharply lower following the Fed's decision with the SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) ending the session 2.98% lower at $586.28 and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) closing 3.61% lower at $516.47.
Expert Ideas: Chris Zaccarelli, chief investment officer for Northlight Asset Management, said that markets are forward-looking and reacted to the Fed's 2025 projection and not the quarter-point cut that it also delivered. 
"Santa came early and dropped a 25-bps rate cut in the market's stocking but accompanied it with a note saying that there would be coal next year," Zaccarelli said.&nbsp;
Bill Adams, chief economist for Comerica Bank, said the Fed is reacting to the incoming Trump administration's policies, which it sees as most likely to boost growth and inflation, as well as tighten the job market. 
Trump does not have much control over the pace of rate cuts in the near term, Adams said, but "that could change in 2026 if President-elect Trump gets the Senate to confirm a new Fed chair who is more sympathetic to his policy goals."
Charlie Ripley, senior investment strategist for Allianz Investment Management, highlighted the growing concerns around inflation and the Fed's dot-plot, which shows shallower rate cuts ahead in both 2025 and 2026. 
"The main takeaway from today's Fed meeting was that inflation risks are back, and the Fed is clearly concerned," Ripley said.&nbsp;
"The Fed has been able to maneuver 100 basis points of cuts so far in this cycle but given the trajectory of the economy and the recent uptick of inflation, it is going to be more difficult for the Fed to provide basis to continue cutting rates at the same pace," he added.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42515463/nike-needs-a-turnaround-after-q2-results-are-released-this-week-will-new-ceo-just-do-it">Nike Needs A Turnaround After Q2 Results Are Released This Week: Will New CEO &#8216;Just Do It?&#8217;</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Macro Economic Events

'Santa Came Early' But Fed Brings 'Coal Next Year': Experts Weigh In On Interest Rate Cut, 2025 Projections

Cognition Therapeutics (CGTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

Positive Buy Rating Reaffirmed for Cognition Therapeutics Amid Promising Alzheimer's Drug Data

Oppenheimer analyst Jay Olson maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report) yesterday and set a price target of $9.00....

Cognition Therapeutics (CGTX) Gets a Buy from Oppenheimer

"In the third quarter and recent weeks Cognition Therapeutics (CGTX) achieved one of the most important milestones in its history as the Phase 2 SH...

Cognition Therapeutics reports Q3 EPS (25c), consensus (22c)

Cash and cash equivalents as of September 30, 2024 were approximately $22.0 million and total grant funds remaining from the NIA were $53.6 million...

Cognition Therapeutics sees cash runway into 2Q25

Cognition Therapeutics GAAP EPS of -$0.25

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q3 earnings. Here is a breakdown of the information Cognition Therapeutics, Inc. presente...

Cognition Therapeutics Reports Promising Q3 2024 Results

Cognition Therapeutics (CGTX) provided an update on a biomarker analysis from the Phase 2 ‘SHINE' study in mild-to-moderate Alzheimer's disease. Th...

Cognition Therapeutics provided an update on Phase 2 'SHINE' study analysis

Cognition Therapeutics (CGTX) announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in pati...

Cognition announces all participants completed final visit in SHIMMER study

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics (CGTX – Research Report) and keeping the price target ...

Positive Clinical Trial Developments and Financial Position Drive Buy Rating for Cognition Therapeutics

Cognition Therapeutics (CGTX) announced topline results from the exploratory Phase 2 ‘SHIMMER' study demonstrating CT1812 produced strong therapeut...

Cognition Therapeutics announces results in Phase 2 study of CT1812

CGTX

Screenshot 2024-12-11 at 6.36.45 PM

Biotech

General

Cognition Therapeutics Hopes To Affirm CT1812 Holds The Key To Slowing Progression Of Dementia With Lewy Bodies

Press Releases

Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Health Care

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Athira Pharma

Cara Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Impact BioMedical

IGC Pharma

Opus Genetics

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

NRX Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Talphera

Traws Pharma

TherapeuticsMD

HC Wainwright & Co.

Chardan Capital

B. Riley Securities

Rodman & Renshaw

Oppenheimer

WIIM

Cognition Therapeutics shares are trading higher after the company announced topline results which met its primary endpoint of safety and tolerability from its exploratory Phase 2 SHIMMER study.

Comments

Cognition Therapeutics

뉴스

에 대한 최신 뉴스 Cognition Therapeutics (NASDAQ:CGTX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌